FR2937251B1 - Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil - Google Patents

Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil

Info

Publication number
FR2937251B1
FR2937251B1 FR0805721A FR0805721A FR2937251B1 FR 2937251 B1 FR2937251 B1 FR 2937251B1 FR 0805721 A FR0805721 A FR 0805721A FR 0805721 A FR0805721 A FR 0805721A FR 2937251 B1 FR2937251 B1 FR 2937251B1
Authority
FR
France
Prior art keywords
hexahydrocyclopenta
pyrrol
benzamide
medicaments
propoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0805721A
Other languages
English (en)
Other versions
FR2937251A1 (fr
Inventor
Pierre Lestage
Laurence Danober
Anita Roger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Priority to FR0805721A priority Critical patent/FR2937251B1/fr
Priority to ARP090103933A priority patent/AR073848A1/es
Priority to PCT/FR2009/001208 priority patent/WO2010043787A1/fr
Publication of FR2937251A1 publication Critical patent/FR2937251A1/fr
Application granted granted Critical
Publication of FR2937251B1 publication Critical patent/FR2937251B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0805721A 2008-10-16 2008-10-16 Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil Expired - Fee Related FR2937251B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0805721A FR2937251B1 (fr) 2008-10-16 2008-10-16 Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
ARP090103933A AR073848A1 (es) 2008-10-16 2009-10-14 Utilizacion de la 4-(3-(hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida para la obtencion de medicamentos destinados al tratamiento de los trastornos del sueno. composicion farmaceutica.
PCT/FR2009/001208 WO2010043787A1 (fr) 2008-10-16 2009-10-15 Utilisation du 4-(3-[hexahydrocyclopenta[c]pyrrol-i(ih)- yl]propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0805721A FR2937251B1 (fr) 2008-10-16 2008-10-16 Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil

Publications (2)

Publication Number Publication Date
FR2937251A1 FR2937251A1 (fr) 2010-04-23
FR2937251B1 true FR2937251B1 (fr) 2011-03-18

Family

ID=40416951

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0805721A Expired - Fee Related FR2937251B1 (fr) 2008-10-16 2008-10-16 Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil

Country Status (3)

Country Link
AR (1) AR073848A1 (fr)
FR (1) FR2937251B1 (fr)
WO (1) WO2010043787A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR2976286B1 (fr) * 2011-06-08 2013-05-24 Servier Lab 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent
FR2976285B1 (fr) * 2011-06-08 2013-05-24 Servier Lab Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
FR2999179A1 (fr) * 2012-12-07 2014-06-13 Servier Lab Procede de synthese d'un sel d'addition a un acide pharmaceutiquement acceptable du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, ainsi que les formes cristallines associees

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
AR073848A1 (es) 2010-12-09
FR2937251A1 (fr) 2010-04-23
WO2010043787A1 (fr) 2010-04-22

Similar Documents

Publication Publication Date Title
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
FR22C1062I1 (fr) Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide
MA28987B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2890562B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
IL213563A (en) History of imidazole and its use in the preparation of drugs for the treatment of central nervous system diseases
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
FR2937251B1 (fr) Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2010006033A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso.
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
PL2019683T5 (pl) Podawanie czynników wzrostu do leczenia zaburzeń OUN
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP1988777A4 (fr) Pyrazoles pour le traitement de l'obésité et d'autres troubles du snc
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
EP1891065A4 (fr) Nouveaux antagonistes du mchr1 et leur utilisation dans le traitement des affections et des troubles induits par le mchr1
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
MA33753B1 (fr) Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
JP2013538206A5 (fr)
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2884714B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
FR2908995B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
IL206615A0 (en) Piperidine sulfonamide derivatives
MA29720B1 (fr) Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20120629